Antifibrotic agents
Pirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). High-cost specialty drugs with frequent step-therapy and lab-monitoring requirements.
What this class is
Antifibrotic agents slow progression of pulmonary fibrosis. FDA-approved for IPF (pirfenidone, nintedanib) and PPF and SSc-ILD (nintedanib). Both require liver function monitoring and have GI tolerability issues. They don't reverse fibrosis but slow FVC decline — early treatment is associated with better outcomes.
Representative drugs
- Pirfenidone (Esbriet)
- Nintedanib (Ofev)
Common denial patterns
- Specific FVC threshold requirements (plan demands ≥50% predicted)
- Step therapy requiring trial of other agent first
- Specialty pharmacy network restrictions
Clinical guidelines that win appeals
- ATS/ERS/JRS/ALAT IPF Guideline 2022
- ATS PPF Guideline 2022
Frequently asked questions
What is antifibrotic agents?
Antifibrotic agents slow progression of pulmonary fibrosis. FDA-approved for IPF (pirfenidone, nintedanib) and PPF and SSc-ILD (nintedanib). Both require liver function monitoring and have GI tolerability issues. They don't reverse fibrosis but slow FVC decline — early treatment is associated with better outcomes.
What are the common denial patterns?
Specific FVC threshold requirements (plan demands ≥50% predicted); Step therapy requiring trial of other agent first; Specialty pharmacy network restrictions.
Which clinical guidelines support appeals?
ATS/ERS/JRS/ALAT IPF Guideline 2022; ATS PPF Guideline 2022.
Related
- Cystic fibrosis & pulmonary fibrosisTrikafta / Kalydeco CFTR modulators, Ofev/Esbriet antifibrotics
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
- GLP-1 receptor agonistsSemaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Sax
Appeal a antifibrotic agents denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com